Key result
Sacubitril/valsartan treatment was associated with substantial improvements in ejection fraction in 75% (6 of 8) of patients with chemotherapy-induced cardiomyopathy.
Why the study?
Chemotherapy-induced cardiotoxicity frequently causes mortality and heart failure, but the effectiveness of sacubitril/valsartan in treating chemotherapy-induced heart failure has not been extensively explored.
Does sacubitril/valsartan improve ejection fraction in patients with chemotherapy-induced cardiomyopathy?
Case Report (n=8)
No
Does sacubitril/valsartan improve ejection fraction in patients with chemotherapy-induced cardiomyopathy?
In a small case series, sacubitril/valsartan was associated with improved ejection fraction in patients with chemotherapy-induced cardiomyopathy.
May suggest benefit in chemotherapy-induced cardiomyopathy; hypothesis-generating and requires prospective trials before practice change.
Background: Chemotherapy-induced cardiotoxicity is a significant problem, ranking as the second most frequent cause of mortality in cancer patients. This adverse outcome encompasses many cardiovascular problems, such as heart failure. Sacubitril/valsartan has shown potential in the management of heart failure, however, its effectiveness in treating chemotherapy-induced heart failure has not been extensively explored. We performed a case series to investigate the safety and effectiveness of sacubitril/valsartan in treating chemotherapy-induced cardiomyopathy in Saudi Arabia. Methods: The case series was conducted at a single medical center in Makkah, Saudi Arabia. The data gathered included patient demographics, clinical features, laboratory results, echocardiographic findings, and medication information. The data underwent analysis using descriptive statistics. Results: Out of the total of eight patients who were part of the investigation, a notable majority of six individuals exhibited substantial enhancements in their ejection fraction (EF) after receiving sacubitril/valsartan medication. Conclusion: Our case series provides significant insights by revealing improvements in ejection fraction (EF) in six out of eight patients who had chemotherapy-induced cardiomyopathy after receiving sacubitril/valsartan treatment.
No takes yet. Share an insight, caveat, or question.
Alshammari et al. (2024) conducted a case report in Chemotherapy-induced cardiomyopathy (n=8). Sacubitril/valsartan was evaluated on Improvement in ejection fraction (EF). Sacubitril/valsartan treatment was associated with substantial improvements in ejection fraction in 75% (6 of 8) of patients with chemotherapy-induced cardiomyopathy.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: